DanCann Pharma A/S is reducing its debt with current lenders through a directed share issue at market conditions
COPENHAGEN, Denmark, 21 March 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, has today, with the support of an authorization from the Extra General Meeting held September 20, 2022, decided on a new share issue of a maximum of 2,031,250 shares at a subscription price of DKK 0.63 per share at a total value of 2 MSEK (the "Share Issue")The reasons for the deviation from the shareholders' preferential rights are mainly to raise capital in a time-efficient manner and to be able to reduce the debt in the Company.